Free Endocrinology CME

Primary care clinicians and endocrinologists play a critical role in identifying and managing metabolic dysfunction-associated steatohepatitis (MASH) before it progresses. Results from a Med-IQ survey, however, revealed that approximately half of the respondents screen only 50% or fewer of their patients with obesity or type 2 diabetes. Patients with these conditions or other risk factors, such as metabolic syndrome, dyslipidemia, or elevated liver enzymes, should be screened using noninvasive tools like FIB-4, transient elastography (FibroScan), ELF, or VCTE.

Although lifestyle modification remains the cornerstone of treatment, pharmacologic options such as GLP-1 receptor agonists, pioglitazone, and resmetirom may be appropriate based on individual risk profiles. Most patients can be effectively managed in primary care or endocrinology settings, with hepatology referral recommended for patients with a high risk of advanced fibrosis.